SCORE

50

REGN: Regeneron Pharmaceuticals, Inc. is a Sell


The current rating for REGN is 50, which is 0% below its historic median rating of 50. This indicates lower risk than normal.


The rating is currently showing a higher than normal reading, suggesting risk levels could be lower than normal.